Journal Watch · Frontiers in Immunology · 2026
Predictive value of peripheral blood eosinophil levels and dynamics for efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer: a real-world study.
This study supports the use of peripheral blood eosinophil-related indices as prognostic and safety biomarkers in NSCLC patients treated with ICIs.
TL;DR
This study supports the use of peripheral blood eosinophil-related indices as prognostic and safety biomarkers in NSCLC patients treated with ICIs.
Key findings
- Regarding safety, 38.4% of patients developed irAEs.
- Higher AEC levels at cycles 2 and 4, as well as early increases from baseline to cycle 2, were associated with an elevated risk of irAEs, while baseline AEC/E% showed no significant association with irAEs.
- This study supports the use of peripheral blood eosinophil-related indices as prognostic and safety biomarkers in NSCLC patients treated with ICIs.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Overall survival (OS) and progression-free survival (PFS) were the primary and secondary endpoints. Associations with irAEs were also evaluated. Multivariable Cox analysis showed that increases in AEC and E% from baseline to cycle 4 (ΔAEC and ΔE%) were independently associated with OS (ΔAEC: aHR=0.88 per doubling, p=0.036; ΔE%: aHR=0.84 per doubling, p=0.006). Optimal cut-offs for cycle 4 AEC (0.22×10<sup>9</sup>/L), E% (2.60%), ΔAEC (0.01×10<sup>9</sup>/L), and ΔE% (0.85%), determined by the minimum p-value method, indicated that values above these thresholds were significantly associated with improved OS and PFS (p<0.05).
Full abstract (original)
Background: Heterogeneous benefits from immunotherapy in advanced driver gene-negative non-small cell lung cancer (NSCLC) underscore the need for biomarkers predicting efficacy and immune-related adverse event (irAE) risk. Eosinophils, routinely measured in peripheral blood and involved in antitumor immunity, may serve as practical biomarkers for predicting the efficacy and safety of immune checkpoint inhibitors (ICIs). This retrospective study enrolled 316 consecutive patients with unresectable stage III-IV NSCLC treated with ICI-based regimens at Harbin Medical University Cancer Hospital (2016-2024). Peripheral absolute eosinophil count (AEC) and eosinophil percent (E%) were measured at baseline and after cycles 2 and 4.
What they did: Overall survival (OS) and progression-free survival (PFS) were the primary and secondary endpoints. Associations with irAEs were also evaluated. Multivariable Cox analysis showed that increases in AEC and E% from baseline to cycle 4 (ΔAEC and ΔE%) were independently associated with OS (ΔAEC: aHR=0.88 per doubling, p=0.036; ΔE%: aHR=0.84 per doubling, p=0.006). Optimal cut-offs for cycle 4 AEC (0.22×10<sup>9</sup>/L), E% (2.60%), ΔAEC (0.01×10<sup>9</sup>/L), and ΔE% (0.85%), determined by the minimum p-value method, indicated that values above these thresholds were significantly associated with improved OS and PFS (p<0.05).
Results & conclusions: Regarding safety, 38.4% of patients developed irAEs. Higher AEC levels at cycles 2 and 4, as well as early increases from baseline to cycle 2, were associated with an elevated risk of irAEs, while baseline AEC/E% showed no significant association with irAEs. This study supports the use of peripheral blood eosinophil-related indices as prognostic and safety biomarkers in NSCLC patients treated with ICIs.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1816610 · PubMed 42148125.
Why it matters for pharma & biotech
- Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Frontiers in Immunology study find?
This study supports the use of peripheral blood eosinophil-related indices as prognostic and safety biomarkers in NSCLC patients treated with ICIs.
What type of study is this?
It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. Overall survival (OS) and progression-free survival (PFS) were the primary and secondary endpoints.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1816610. PubMed ID: 42148125. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/predictive-value-of-peripheral-blood-eosinophil-levels-and-dynamics-for-816610/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides